GSK plc/£GSK
1D1W1MYTD1Y5YMAX
Capital at risk
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
- Ticker
- £GSK
- Sector
- Health
- Primary listing
- LSE
- Employees
- 66,841
- Headquarters
- London, United Kingdom
- Website
- www.gsk.com
GSK plc Metrics
BasicAdvanced
£75B
15.77
£1.18
0.29
£0.67
3.60%
Price and volume
Market cap
£75B
Beta
0.29
52-week high
£22.82
52-week low
£14.55
Average daily volume
5.5M
Dividend rate
£0.67
Financial strength
Current ratio
0.815
Quick ratio
0.519
Long term debt to equity
0.815
Total debt to equity
1.065
Dividend payout ratio (TTM)
55.30%
Interest coverage (TTM)
14.62%
Profitability
EBITDA (TTM)
10,818
Gross margin (TTM)
73.49%
Net profit margin (TTM)
14.52%
Operating margin (TTM)
29.17%
Effective tax rate (TTM)
10.86%
Revenue per employee (TTM)
£500,000
Management effectiveness
Return on assets (TTM)
10.01%
Return on equity (TTM)
33.38%
Valuation
Price to earnings (TTM)
15.775
Price to revenue (TTM)
2.252
Price to book
4.26
Price to tangible book (TTM)
-11.51
Price to free cash flow (TTM)
13.06
Free cash flow yield (TTM)
7.66%
Free cash flow per share (TTM)
1.423
Dividend yield (TTM)
3.60%
Growth
Revenue change (TTM)
4.97%
Earnings per share change (TTM)
42.63%
3-year revenue growth (CAGR)
4.22%
10-year revenue growth (CAGR)
2.81%
3-year earnings per share growth (CAGR)
-32.10%
10-year earnings per share growth (CAGR)
65.27%
3-year dividend per share growth (CAGR)
7.01%
10-year dividend per share growth (CAGR)
-3.78%
What the Analysts think about GSK plc
Analyst ratings (Buy, Hold, Sell) for GSK plc stock.
Analyst projections of the future price of GSK plc stock.
Bulls say / Bears say
GSK delivered strong second-quarter momentum in higher-growth businesses: Specialty Medicines sales rose 14%, HIV grew 10%, Oncology 17%, and Vaccines 8%, supporting 9% growth in core EPS. (Reuters)
Management is sharply accelerating the pipeline, targeting more than 20 Phase III trial starts in 2026 versus a prior target of 10 and prioritising seven assets across 18 indications. (Reuters)
The £1.9 billion annual-savings programme by 2029 could fund late-stage R&D and help protect profitability, while GSK’s £400 million Cambridge R&D investment may improve access to scientific and clinical talent. (Reuters)
GSK faces a material patent cliff as dolutegravir exclusivity begins to roll off between 2028 and 2030, potentially pressuring HIV revenue and margins. (Reuters)
Growth remains uneven: second-quarter General Medicines sales fell 9%, while Trelegy sales declined 7%, highlighting pressure on older respiratory products. (Reuters)
Pipeline execution remains a risk after GSK stopped developing its chronic-cough drug camlipixant following failed late-stage trials; the setback contributed to a £1.3 billion impairment in the second quarter. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 14 Sept 2026.
GSK plc Financial Performance
Revenues and expenses
GSK plc Earnings Performance
Company profitability
Upcoming events
Funds containing GSK plc
AllEURGBPUSD
Fund name | Fund size | £GSK weighting |
|---|---|---|
iShares MSCI Europe Health Care Sector€ESIH | €863M | 5.75% |
iShares MSCI Europe Health Care Sector£ESIH | £741M | 5.75% |
iShares STOXX Europe 600 Health Care€EXV4 | €687M | 5.51% |
iShares Edge MSCI Europe Value Factor€CEMS | €2.6B | 2.94% |
iShares Edge MSCI Europe Value Factor£IEFV | £2.2B | 2.94% |
Latest price is delayed by 15 minutes. Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by London Stock Exchange, through Infront.